COMP <GO>
ELAN vs RDY // ALTMAN Z-SCORE & DEBT/EQUITY
Elanco Animal Health Incorporated (NYSE) VS. Dr. Reddy's Laboratories Ltd (NYSE) • 15-METRIC TALLY: ELAN 2
— RDY 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: RDY
LAST: $24.10 (+4.51%) • MKT CAP: $11.52B
balance-sheet
1.24
LAST: $14.13 (-0.28%) • MKT CAP: $11.83B
balance-sheet
3.74
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELAN VS. RDY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELAN | RDY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.50% | 9.90% | -12.40 | RDY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 21.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.45% | 2.21% | +0.24 | ELAN | /fcf-yield <GO> |
| Operating Margin | -6.00% | 13.90% | -19.90 | RDY | /operating-margins <GO> |
| Net Profit Margin | -4.90% | 10.90% | -15.80 | RDY | /net-margins <GO> |
| Revenue Growth (YoY) | 6.20% | 6.60% | -0.40 | RDY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 1.24 | 3.74 | -2.50 | RDY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | RDY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.9 | 76.2 | -24.30 | RDY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.05 | -0.09 | RDY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 30.5x | -10.50 | ELAN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.52B | $11.83B | -$305.8M | RDY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELAN REV | RDY REV | ELAN GROSS % | RDY GROSS % | ELAN FCF | RDY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.71B | — | 55.0% | — | $284.0M | — |
| FY 2024 | $4.44B | — | 54.9% | — | $394.0M | — |
| FY 2023 | $4.42B | — | — | — | $72.2M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELAN // BETA 0.96
RDY // BETA 1.05